Patents Examined by Jerry D. Johnson
  • Patent number: RE48557
    Abstract: Methods of inhibiting the growth or metastasis of a cancer in a subject by inhibiting a Ral GTPase in the subject, and small molecule inhibitors of Ral GTPases useful in the methods of the invention. Pharmaceutical compositions containing the compounds of the invention, and methods of using the same.
    Type: Grant
    Filed: August 27, 2019
    Date of Patent: May 18, 2021
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Dan Theodorescu, Michael Fitzpatrick Wempe, David Ross, Chao Yan, Phillip Reigan
  • Patent number: RE48622
    Abstract: A series of pyrazolo[3,4-d]pyrimidine derivatives that are substituted at the 4-position by a diaza monocyclic, bridged bicyclic or spirocyclic moiety, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: July 6, 2021
    Assignees: UCB Biopharma SRL, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Daniel James Ford, Richard Jeremy Franklin, Anant Ramrao Ghawalkar, Helen Tracey Horsley, Qiuya Huang, James Thomas Reuberson, Bart Vanderhoydonck
  • Patent number: RE48658
    Abstract: A decrease in an NOx removal or reduction rate at the time of filter regeneration is suppressed. To this end, provision is made for an NOx selective reduction catalyst, a filter arranged at the upstream side of the NOx selective reduction catalyst, an NH3 generation catalyst arranged at the upstream side of the NOx selective reduction catalyst to generate NH3 when the air fuel ratio of an exhaust gas is equal to or less than a stoichiometric air fuel ratio, a regeneration unit to carry out regeneration of the filter, and a generation unit to make the air fuel ratio of the exhaust gas equal to or less than the stoichiometric air fuel ratio, thereby causing NH3 to be generated in the NH3 generation catalyst, wherein the regeneration unit inhibits the regeneration of the filter until the generation of NH3 by the generation unit is completed.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: July 27, 2021
    Assignee: TOYOTA JIDOSHA KABUSHIKI KAISHA
    Inventor: Yasuyuki Irisawa
  • Patent number: RE48687
    Abstract: The present invention relates to pyridinylaminopyrimidine derivatives represented by the following formula (I), and pharmaceutically acceptable salts, preparation process and use thereof, wherein R1, R2, R3, R4, R5, m and A are defined as in the description. Pyridinylaminopyrimidine derivatives of the present invention can selectively inhibit the activity of mutant-type epidermal growth factor receptor (EGFR), have a good inhibition for the cancer cell proliferation, and therefore can be used as a therapeutic agent for treating tumors and relevant diseases.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: August 17, 2021
    Assignee: Shanghai Allist Pharmaceuticals Co., Ltd.
    Inventors: Huibing Luo, Huayong Zhou, Shuhui Wang, Yong Wu
  • Patent number: RE48730
    Abstract: A composite material including silanated filler and mixed polymerizable monomer, having a stable pasty property which keeps well and has a consistent usability. A composite material containing a silanated filler, a polymerizable monomer, and a polymerization initiator, and may be produced by a process which includes a mixed polymerizable monomer preparing step, a silanation step, a silanated filler preserving step, a composite material preparing step, a composite material preserving step, a composite material filling step, and a small quantity preserving container preserving step.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: September 14, 2021
    Assignee: SHOFU INC.
    Inventors: Yusei Kadobayashi, Masako Shigezawa
  • Patent number: RE48839
    Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: December 7, 2021
    Assignee: Intra-Cellular Therapies, Inc
    Inventors: Sharon Mates, Allen Fienberg, Lawrence Wennogle
  • Patent number: RE48842
    Abstract: Provided herein are benzopyrimido-pyrrolo-oxazine-dione (BPO) compounds and pyrimido-pyrrolo-quinoxalinedione (PPQ) compounds, and compositions comprising these compounds, that inhibit cystic fibrosis transmembrane conductance regulator (CFTR) mediated ion transport and that are useful for treating diseases and disorders associated with aberrantly increased CFTR chloride channel activity, such as polycystic kidney disease and secretory diarrheas. The compounds and compositions comprising the compounds described herein may be used for inhibiting expansion or preventing formation of cysts in persons who have polycystic kidney disease.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: December 7, 2021
    Assignee: The Regents of the University of California
    Inventors: Alan S. Verkman, David S. Snyder
  • Patent number: RE48854
    Abstract: The invention relates to compositions comprising abscisic acid, and/or salts, derivatives and analogs thereof, and methods of using the same for improving the health and survival of animal offspring.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: December 21, 2021
    Assignee: VALENT BIOSCIENCES LLC
    Inventors: Maria Pilar Herrero, Warren E. Shafer
  • Patent number: RE48861
    Abstract: The present technology provides a process of reducing, removing or eliminating organohalo, glycidol, and oxirane species from carboxylic acid esters streams and crude and refined triglyceride oils to provide a carboxylic acid ester stream or triglyceride oil with reduced levels or essentially free of organohalo, glycidyl or other oxirane species. The process includes adding to the carboxylic acid ester stream or triglyceride oil an amount of a carboxylate anion and a cation counterion sufficient to react with the organohalo, glycidyl and oxirane species present.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: December 28, 2021
    Assignee: STEPAN SPECIALTY PRODUCTS, LLC
    Inventors: Joseph C. Rongione, Jenifer Heydinger-Galante
  • Patent number: RE48890
    Abstract: Methods of treating, preventing and/or managing cancer as well as and diseases and disorder associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: January 11, 2022
    Assignee: Celgene Corporation
    Inventor: Jerome B. Zeldis
  • Patent number: RE48948
    Abstract: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine in a drug depot at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain. When appropriate drug depot formulations are provided within biodegradable polymers, this pain relief can be continued for at least fourteen days.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: March 1, 2022
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Danielle L. Clay, Josee Roy, William F. McKay
  • Patent number: RE48992
    Abstract: The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: March 29, 2022
    Assignee: Helmholtz Zentrum München-Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
    Inventors: Marcus Conrad, Joel Schick, Bettina Proneth, Peter Sennhenn
  • Patent number: RE49006
    Abstract: The invention relates to the use of additives in the preparation of crop protection composition spray mixtures, in particular as additives for tank mixtures of specific pesticides according to formula (I), pesticide mixtures and crop protection compositions comprising these pesticides.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: April 5, 2022
    Assignee: Syngenta Participations AG
    Inventors: Christian Popp, Anke Buchholz, Fabienne Hatt
  • Patent number: RE49022
    Abstract: The present invention relates to novel bisamide derivatives of formula (I) having insecticidal activity, to processes and intermediates for preparing them, to insecticidal, acaricidal, nematicidal or molluscicidal compositions comprising them and to methods of using them to combat and control insect, acarine, nematode or mollusc pests wherein X0, X1, X2, Y1, Y2, R1, R2, G1 and G2, and Q are as described in formula 1 or salts and n-Oxides thereof.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: April 12, 2022
    Assignee: SYNGENTA PARTICIPATIONS AG
    Inventors: Andrew Edmunds, Andre Stoller, Thomas Pitterna
  • Patent number: RE49085
    Abstract: An agricultural potassium-fertigation method for emitter-irrigation potassium fertigation feeds a potassium-nutrient feedstock comprised of potassium formate and water to an active emitter-irrigation system continuously, or substantially continuously, at low levels, during the entire time, or substantially the entire time, that irrigation water is sufficiently flowing through the irrigation system during a prolonged term.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: May 31, 2022
    Inventors: John C. Miller, Deborah L. Miller
  • Patent number: RE49080
    Abstract: This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: May 24, 2022
    Assignee: Novartis AG
    Inventors: Gregory Raymond Bebernitz, Mark G. Bock, Dumbala Srinivas Reddy, Atul Kashinath Hajare, Vinod Vyavahare, Sandeep Bhausaheb Bhosale, Suresh Eknath Kurhade, Videsh Salunkhe, Nadim S. Shaikh, Debnath Bhuniya, P. Venkata Palle, Lili Feng, Jessica Liang
  • Patent number: RE49111
    Abstract: [Problem] To provide a compound which is useful as an active ingredient for a pharmaceutical composition for preventing or treating urine storage dysfunction, voiding dysfunction, lower urinary tract dysfunction, and the like. [Means for Solution] The present inventors have found that a thiazole derivative substituted with pyrazinylcarbonylamino at the 2-position is an excellent muscarinic M3 receptor-positive allosteric modulator and is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, thereby completing the present invention. 2-Acylaminothiazole derivative or a salt thereof of the present invention is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, for example voiding dysfunction such as underactive bladder.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: June 21, 2022
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Taisuke Takahashi, Takanori Koike, Kenji Negoro, Hiroaki Tanaka, Jun Maeda, Kazuhiro Yokoyama, Hajime Takamatsu
  • Patent number: RE49154
    Abstract: The invention relates to a process for producing LPG and BTX, comprising a) subjecting a mixed hydrocarbon stream to first hydrocracking in the presence of a first hydrocracking catalyst to produce a first hydrocracking product stream; b) separating the first hydrocracking product stream to provide at least a light hydrocarbon stream comprising at least C2 and C3 hydrocarbons, a middle hydrocarbon stream consisting of C4 and/or C5 hydrocarbons and a heavy hydrocarbon stream comprising at least C6+ hydrocarbons and c) subjecting the heavy hydrocarbon stream to second hydrocracking in the presence of a second hydrocracking catalyst to produce a second hydrocracking product stream comprising BTX, wherein the second hydrocracking is more severe than the first hydrocracking, d) wherein at least part of the middle hydrocarbon stream is subjected to C4 hydrocracking optimized for converting C4 hydrocarbons into C3 hydrocarbons in the presence of a C4 hydrocracking catalyst to produce a C4 hydrocracking product strea
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: August 2, 2022
    Assignee: SABIC GLOBAL TECHNOLOGIES B.V.
    Inventors: Arno Johannes Maria Oprins, Andrew Mark Ward, Andrew P. Davies, Kae Shin Wong, Luis Aramburo, Maikel Van Iersel
  • Patent number: RE49220
    Abstract: A filter element (1) has an inner body (12) and an outer body (11). One casing body (12) has a cross section deviating from circularity. Body contact surfaces (20, 21) face one another for the contact of essentially all filter folds (18a-18f, 18I-18III) of a pleated filter web (10). The filter folds (18a-18f, 18I-18III), in terms of fold height (h), are divided into individual groups (I, II) each having several filter folds (18I-18II) of a common fold height (hmax, hmin) alongside one another in sections. Between two adjacent filter folds (18a-18f, 18I-18III) of different groups (I, II) filter folds are arranged (18b-18e; 18m) of at least one third group (III).
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: September 27, 2022
    Assignee: RT-FILTERTECHNIK GMBH
    Inventors: Gerhard Stehle, Dirk Schoenfeld
  • Patent number: RE49223
    Abstract: The present invention provides a water-soluble fluorescent compound of resveratrone 6-O-?-glucoside [(E)-4-(8-hydroxy-6-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)naphthalen-2-yl)but-3-en-2-one] and its derivatives of Formula I which have at least one water-soluble substituent, and a method for preparing the same by a photochemical reaction of resveratrol 3-O-?-glucoside and its derivatives of having Formula 3 which are not fluorescent. Said new water-soluble fluorescent compounds has single-photon absorptive characteristics and/or two-photon absorptive characteristics as well as no or little toxicity, and can be usefully utilized in fields that requires water-soluble fluorescent characteristics (diagnosis, fluorescent probe, in vivo imaging, display, etc.).
    Type: Grant
    Filed: April 29, 2020
    Date of Patent: September 27, 2022
    Assignees: SNU R&DB FOUNDATION;, GLOBAL FRONTIER CENTER FOR MULTISCALE ENERGY SYSTEMS
    Inventors: Seong Keun Kim, Il Seung Yang, Seon Jin Hwang, Jung Eun Lee, Jong Woo Lee, Jun Hee Kang, Eun Hak Lim